Melatonin and the metabolic syndrome: a tool for effective therapy in obesity‐associated abnormalities?
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The metabolic syndrome (M et S) is a cluster of metabolic abnormalities associated with increased risk for cardiovascular diseases. Apart from its powerful antioxidant properties, the pineal gland hormone melatonin has recently attracted the interest of various investigators as a multifunctional molecule. Melatonin has been shown to have beneficial effects in cardiovascular disorders including ischaemic heart disease and hypertension. However, its role in cardiovascular risk factors including obesity and other related metabolic abnormalities is not yet established, particularly in humans. New emerging data show that melatonin may play an important role in body weight regulation and energy metabolism. This review will address the role of melatonin in the M et S focusing on its effects in obesity, insulin resistance and leptin resistance. The overall findings suggest that melatonin should be exploited as a therapeutic tool to prevent or reverse the harmful effects of obesity and its related metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Global burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319 · cited 2×
“Previous strategies to combat the prevalence of obesity and the MetS have not yet been successful and it is predicted that up to 58% of the global adult population could be either overweight or obese by 2030 (Kelly et al. 2008).”
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Reactive oxygen species have a causal role in multiple forms of insulin resistance
Houstis, N., Rosen, E. D., & Lander, E. S. (2006) · Nature · doi:10.1038/nature04634 · Cited by 2,525 · cited 1×
“…oxidative stress and eventual antioxidant interventions in obesity and insulin resistant states will not be discussed since they have been largely reviewed elsewhere (Houstis et al. 2006, Vincent et al. 2007, Grattagliano et al. 2008, Hopps et al. 2010, Otani 2011, Rains & Jain 2011).”
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Tan, D., Manchester, L. C., Terron, M. P., Flores, L. J., & Reiter, R. J. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00407.x · Cited by 1,601 · cited 2×
“Furthermore, several melatonin metabolites (e.g., N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK)) which are formed when melatonin neutralizes damaging reactants are themselves free radical scavengers (Tan et al. 2007, Reiter et al. 2008).”
Mechanisms of leptin action and leptin resistance.
Myers, M. G., Cowley, M. A., & Münzberg, H. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100707 · Cited by 1,074 · cited 2×
“…of leptin resistance and impaired leptin signaling includes amongst other things increased activity of suppressor of cytokine signaling 3 (SOCS3) (Bjorbaek et al. 1999, Emilsson et al. 1999) which is a member of a family of proteins which inhibits the JAK-STAT signaling cascade (Myers et al. 2008).”
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 6×
“As indicated above, melatonin exerts its physiological functions through its chronobiotic, anti-excitatory, antioxidant, anti-inflammatory, immunomodulatory and vasomotor activities (Pandi-Perumal et al. 2006).”
InfluentialObesity, insulin resistance and free fatty acids
Boden, G. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283444b09 · Cited by 848 · cited 1×
“In this regard, several mechanisms in connection with increased body fat accumulation and insulin resistance have been proposed including, amongst others, generation of lipid metabolites, inflammation, and cellular stress (oxidative and endoplasmic reticulum stress) (for review see Boden (2011)).”
Melatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
The role of SOCS-3 in leptin signaling and leptin resistance
Bjørbæk, C., El-Haschimi, K., Frantz, J. D., & Flier, J. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30059 · Cited by 639
Melatonin: Action as antioxidant and potential applications in human disease and aging
Bonnefont-Rousselot, D., & Collin, F. (2010) · Toxicology · doi:10.1016/j.tox.2010.04.008 · Cited by 320 · cited 3×
“…of toxic reactants including reactive oxygen species (ROS) and free radicals (Reiter et al. 2000, Reiter et al. 2008) and no toxicity was found when melatonin was administered to experimental animals or humans at doses varying between 1mg and 300mg per day (Bonnefont-Rousselot & Collin 2010)).”
Melatonin, endocrine pancreas and diabetes
Peschke, E. (2008) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00519.x · Cited by 309 · cited 4×
“Indeed, melatonin administration inhibits insulin secretion in rat pancreatic islets (Picinato et al. 2 002, Peschke 2008) and could explain why melatonin reduced the fasting insulin levels (Puchalski et al. 2003, She et al. 2009).”
InfluentialClinical Uses of Melatonin: Evaluation of Human Trials
Sanchez-Barcelo, E. J., Mediavilla, M. D., Tan, D. X., & Reiter, R. J. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791233689 · Cited by 301 · cited 1×
“Melatonin is an affordable, cheap and nontoxic molecule with exceptional potential to have a profound effect on public health (Reiter & Korkmaz 2008, Sanchez-Barcelo et al. 2010).”
Koziróg, M., Poliwczak, A. R., Duchnowicz, P., Koter-Michalak, M., Sikora, J., & Broncel, M. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00835.x · Cited by 299 · cited 6×
“…blood pressure (Kitajima et al. 2001) and heart function (Abete et al. 1997) directly and/or indirectly by affecting cardiovascular risk factors including, amongst others, increased visceral fat accumulation and dyslipidaemia (Agil et al. 2011a, Kozirog et al. 2011, Nduhirabandi et al. 2011).”
InfluentialMcLaughlin, T., Allison, G., Abbasi, F., Lamendola, C., & Reaven, G. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.032 · Cited by 268 · cited 1×
“Although not all overweight/ obese persons develop insulin resistance and a normal weight does not equate to insulin sensitivity (McLaughlin et al. 2004), obesity is the most important factor in the etiology of insulin resistance (Cornier et al. 2008).”
Insulin and Leptin as Adiposity Signals
Benoit, S. C. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.267 · Cited by 266
Effects of circadian disruption on the cardiometabolic system
Rüger, M., & Scheer, F. A. J. L. (2009) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-009-9122-8 · Cited by 232 · cited 1×
“Indeed, the CVS is connected to the SCN via multisynaptic autonomic neurons, and evidence confirmed that melatonin affects the CVS via these activities (Ruger & Scheer 2009, Dominguez-Rodriguez et al. 2010).”
Gitto, E., Tan, D.-X., Reiter, R. J., Karbownik, M., Manchester, L. C., Cuzzocrea, S., Fulia, F., & Barberi, I. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011777747 · Cited by 196 · cited 3×
“Beside these metabolic effects, the antioxidant activities of melatonin were also demonstrated in animal models of diet-induced obesity: daily melatonin administration to obese rabbits (1mgkg -1 subcutaneously for 4 weeks)(Hussein et al. 2007) or rats (4mgkg -1 , ip for 8 weeks) (She et al. 2009) improved the metaboli…”
Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats
Agil, A., Rosado, I., Ruiz, R., Figueroa, A., Zen, N., & Fernández‐Vázquez, G. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00928.x · Cited by 169 · cited 6×
“…blood pressure (Kitajima et al. 2001) and heart function (Abete et al. 1997) directly and/or indirectly by affecting cardiovascular risk factors including, amongst others, increased visceral fat accumulation and dyslipidaemia (Agil et al. 2011a, Kozirog et al. 2011, Nduhirabandi et al. 2011).”
InfluentialMelatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene
Mulder, H., Nagorny, C. L. F., Lyssenko, V., & Groop, L. (2009) · Diabetologia · doi:10.1007/s00125-009-1359-y · Cited by 169
New evidence for a role of melatonin in glucose regulation
Peschke, E., & Mühlbauer, E. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.09.001 · Cited by 137 · cited 3×
“However, in the case of type 2 diabetes, as pointed out by Peschke & Muhlbauer (2010), the exploitation of melatonin’s inhibitory effect on insulin secretion as a potential therapy to reduce hyperinsulinaemia requires prudence and more large clinical studies.”
InfluentialHa, E., Yim, S., Chung, J., Yoon, K., Kang, I., Cho, Y. H., & Baik, H. H. (2006) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00334.x · Cited by 124 · cited 3×
“In addition, the role of PKB/Akt is not clear in view of the different results that have been reported showing its activation in skeletal muscle cells (Ha et al .”
She, M., Deng, X., Guo, Z., Laudon, M., Hu, Z., Liao, D., Hu, X., Luo, Y., Shen, Q., & Su, Z. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.005 · Cited by 118 · cited 9×
“This was evidenced by studies using the melatonin agonist NEU-P11 (10mg kg -1 per day for 8 weeks, ip) (She et al. 2009) or Ramelteon, a potent selective MT1/MT2 receptor agonist (8 mg kg -1 per day for 8 weeks, oral) (Oxenkrug & Summergrad 2010): it was found that melatonin agonist administration…”
InfluentialMelatonin improves metabolic syndrome induced by high fructose intake in rats
Kitagawa, A., Ohta, Y., & Ohashi, K. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00955.x · Cited by 116 · cited 7×
“Although 2 weeks of melatonin administration (1 or 10 mg kg 1 day (1), ip starting at 4 weeks) did not affect the body weight of rats fed a high-fructose diet for 6 weeks, it ameliorated insulin resistance (Kitagawa et al. 2011).”
Influential
Cited by
Melatonin: Exceeding Expectations
Reiter, R. J., Tan, D. X., & Galano, A. (2014) · Physiology · doi:10.1152/physiol.00011.2014 · Cited by 605
The Effects of Light at Night on Circadian Clocks and Metabolism
Fonken, L. K., & Nelson, R. J. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1051 · Cited by 460
Hardeland, R. (2013) · Journal of Pineal Research · doi:10.1111/jpi.12090 · Cited by 284
Szewczyk‐Golec, K., Woźniak, A., & Reiter, R. J. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12257 · Cited by 153
Bahrami, M., Cheraghpour, M., Jafarirad, S., Alavinejad, P., Asadi, F., Hekmatdoost, A., Mohammadi, M., & Yari, Z. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102452 · Cited by 60
Metadata
- Authors
- Nduhirabandi, F., du Toit, E. F., & Lochner, A.
- Venue
- Acta Physiologica
- Publisher
- Wiley
- Published
- 2012-02-03
- Volume
- 205
- Issue
- 2
- Pages
- 209-223
- ISSN
- 1748-1708 (ISSN-L)
- 1748-1716
- OpenAlex
- W2136530496
- Cited by
- 116
- References
- 25
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.